RMC-9805 is named as an intervention in 4 current clinical trials in our USA register. 4 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Revolution Medicines, Inc (3). The most-studied condition is PDAC.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer
|
Phase 1/2 | Recruiting | Revolution Medicines, Inc. | USA |
|
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062 · ClinicalTrials.gov ↗ · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma
|
Phase 1/2 | Recruiting | Revolution Medicines, Inc. | USA |
|
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591 · ClinicalTrials.gov ↗ · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
|
Phase 1/2 | Recruiting | Tango Therapeutics, Inc. | USA |
|
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1 | Recruiting | Revolution Medicines, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| PDAC | 2 |
| Non-Small Cell Lung Cancer, NSCLC | 1 |
| KRAS, NRAS, HRAS-mutated NSCLC | 1 |
| KRAS G12C-mutated Solid Tumors, Lung Cancer | 1 |
| Lung Cancer Stage IV, Advanced Solid Tumor, Cancer | 1 |
| PDAC - Pancreatic Ductal Adenocarcinoma | 1 |
| NSCLC | 1 |
| RAS Mutation | 1 |
| Colorectal Cancer | 1 |
| CRC | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
| Colorectal Cancer (CRC) | 1 |
| Pancreatic Ductal Adenocarcinoma (PDAC) | 1 |
| Advanced Solid Tumors | 1 |
| Lead sponsor | Trials |
|---|---|
| Revolution Medicines, Inc. | 3 |
| Tango Therapeutics, Inc. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 4 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our USA register name RMC-9805 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 4 trials are recruiting: 4 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Revolution Medicines, Inc (3) and Tango Therapeutics, Inc (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RMC-9805 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RMC-9805 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RMC-9805 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.